Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07249125
Starting soon Observational

Safety and Quality of Life of Three Treatment Strategies for Low-Risk Papillary Thyroid Microcarcinoma

NCT07249125 · tracked via the Priya Life Science China tracker
Sponsor
Xijing Hospital
Phase
Observational
Started
2025-12-01
Last updated
2025-11-25

Condition(s) studied

Papillary Thyroid Microcarcinoma

Study summary

This is a prospective observational patient registry study designed to evaluate the safety and quality of life associated with three treatment strategies for patients diagnosed with low-risk papillary thyroid microcarcinoma (PTMC): surgical resection, thermal ablation, and active surveillance.

The study aims to collect standardized, real-world clinical data from participating centers. Patients will receive one of the three treatment strategies according to clinical judgment and personal preference. The study team will prospectively follow participants to record safety events, disease progression, and patient-reported quality of life outcomes.

By comparing the outcomes among the three treatment groups, this registry seeks to provide evidence to support personalized and evidence-based decision-making for the management of low-risk PTMC.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * A single papillary thyroid carcinoma (PTC) lesion with a maximum diameter ≤ 1 cm confirmed by imaging. * No evidence of extrathyroidal extension on imaging studies. * No clinical or radiologic evidence of cervical lymph node metastasis. * No evidence of distant metastasis. * Histopathological confirmation of papillary thyroid carcinoma. * The patient has provided written informed consent and agrees to select one of the predefined management strategies (surgical resection, thermal ablation, or active surveillance). Exclusion Criteria: * Ultrasound-confirmed tumor with a maximum diameter \> 1 cm. * Imaging findings (ultrasound/CT/MRI) suggestive of extrathyroidal extension. * Tumor located adjacent to critical structures (e.g., trachea, esophagus, or recurrent laryngeal nerve) with possible invasion risk. * History of thyroidectomy, radiofrequency/microwave/laser ablation, or radioactive iodine therapy. * Failure to provide written informed consent.

Primary outcome measure(s)

  • Rate of lymph node metastasis confirmed by imaging and fine-needle aspiration within 10 years — 10 years
    The proportion of participants who show radiologic evidence of lymph node metastasis confirmed by fine-needle aspiration during 10 years of follow-up.

Trial sites (1)

FacilityCityRegionStatus
Xijing hospital Xi'an Shaanxi

More Xijing Hospital trials in China

Videodensitometric Angiographic Assessment of AR in the Cath-lab for Intraprocedural Guidance of TAVI in CHINA Enrolling by invitation
Ex Vivo Perfusion of Gene-Edited Porcine Livers in Patients With Severe Hepatic Failure Active, not recruiting
A Study on the Treatment of Early Small Breast Cancer With Ultrasound-guided Vacuum-assisted Excision Combined With Surgery Active, not recruiting
The Feasibility of taVNS on Pregnancy Outcomes of Infertility Patients Undergoing IVF Recruiting
Study of Individualized, Precise and Standardized Cervical Open-door Surgery for Cervical Spinal Stenosis Recruiting

Other trials for the same condition

Efficacy and Prognosis of Microwave Ablation Treatment for Papillary Thyroid Microcarcinoma Assessed by Contrast-Enhanced Ultrasound Combined With Genetic and Molecular Diagnostics: A Prospective Observational Study Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07249125 on ClinicalTrials.gov ↗ ← All trials in China